Spondyloarthritis & psoriatic arthritis
Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study
Authors' conclusion
This long-term reassessment reveals significant diagnostic changes in SpA and a mortality burden mainly attributed to infections and CV diseases.
Study context
- Population
- Patients with spondyloarthritis (SpA) fulfilling European Spondyloarthropathy Study Group criteria from the 2004 Spanish REGISPONSER registry, re-evaluated in 2021411 re-evaluated
- Participants
- 536 patients
- Outcome
- Diagnostic change at REGISPON-3 visit
- Follow-up
- 17 years
Methodological detailstwo-timepoint, 17-year reassessment, multivariable logistic regression, Kaplan-Meier survival analysis
- Two-timepoint
- 17-year reassessment
- Multivariable logistic regression
- Kaplan-Meier survival analysis
Main finding
As reported in the abstract
Change in diagnosis among 411 re-evaluated patients, mainly undifferentiated SpA to axSpA or PsA
31.6%
Observational data: associations, not effects.
Further findings
bDMARD use
- bDMARD use at baseline
- 13.1%
- bDMARD use at REGISPON-3
- 52.1%
Median time to first bDMARD
- From symptom onset, years
- 32 (95% CI 30 to 35)
- From diagnosis, years
- 28 (95% CI 26 to 32)
Leading causes of death among 125 deceased
- Infections
- 21.6%
- Cardiovascular (CV) events
- 20.0%
- Cancer
- 19.2%
Original publication
Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study. RMD Open. Published 5 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →